Crucell N.V. Doubles Production of Quinvaxem(R) in 2008 and Prepares Move to New Korean Production Site to Facilitate Growth

LEIDEN, NETHERLANDS--(Marketwire - October 21, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that an agreement was reached to relocate Crucell's Korean production facility, where its pentavalent children's vaccine Quinvaxem® and a hepatitis B vaccine Hepavax-Gene® are produced, from the Shingal site in Yongin City, Korea to the Incheon Free Economic Zone.
MORE ON THIS TOPIC